Carcinoembryonic antigen (CEA, CEACAM5) is expressed on several human carcinomas including colon cancer. CEA contains signal peptides that target the protein through the endoplasmic reticulum and to the cell membrane. We constructed a plasmid DNA vaccine encoding a truncated CEA (DCEA), devoid of its signal peptides, and demonstrated that it was retained inside the cell, while full-length CEA (wtCEA) was expressed on the membrane. We hypothesized that intracellular retention of DCEA would enhance MHC class I presentation of CEA peptides, thus favoring cellular immune responses. In addition, a promiscuous T-helper epitope (Q830-L844 of tetanus toxoid) was fused to the N-terminal of the truncated CEA gene (tetDCEA). C57BL/6 mice immunized with DNA encoding wtCEA or tetDCEA developed both humoral and cellular immune responses to CEA. SCID mice transplanted with spleen cells from tetDCEA but not wtCEA-immunized C57BL/6 mice showed strong suppression of tumor growth after inoculation of human CEA-expressing colon carcinoma cells. Immune spleen cell populations depleted for either B, T or both B and T cells were active, indicating that effector cells might also reside in other populations. The present approach to manipulating antigen presentation may open new possibilities for immunotherapy against colon and other CEA-secreting carcinomas.
C olon cancer accounts for 10-15% of cancer deaths in the industrialized world, second only to lung cancer. Despite improvements in surgery, chemotherapy and radiotherapy, survival rates are only moderate (40% survive longer than 5 years) and have remained essentially unchanged for the last 20 years. Like many solid tumors, colon cancer may relapse after surgery, probably because of the persistence of micrometastases.
Carcinoembryonic antigen (CEA, also called CEA-CAM5 3 ) is a 180 kDa GPI-linked membrane glycoprotein (Fig 1) expressed extensively on most human colon, gastric, and pancreatic carcinomas, as well as on approximately 70% of nonsmall-cell lung carcinomas and 50% of breast cancers. CEA is also expressed on fetal gut tissue and to some extent on normal colonic epithelium. 1, 3 It has an approximately 70% homology with nonspecific cross-reacting antigen (NCA), expressed in normal granulocytes. 4 CEA is synthesized as a precursor protein with N-and C-terminal signal peptides.
These signal peptides target the protein through the endoplasmic reticulum (ER), where it is heavily glycosylated, and subsequently to the cell membrane. Both signal peptides are removed during post-translational processing. The mature protein contains an N-terminal variable region (107 amino acids) and three sets of constant Ig-like repeat regions (178 amino acids each); the C-terminal signal peptide has been replaced by a glycosylphosphatidylinositol (GPI) membrane anchor 5 (Fig 1) . The main clinical use of serum CEA has been in postoperative surveillance of colon cancer.
The immunogenicity of endogenous CEA is poor. 6, 7 Some reports of CEA:anti-CEA complexes in patients exist, 8, 9 but others claim that such findings are artefactual. 10, 11 Evidence of T-cell responses is scarce, although a response of patient T cells to CEA has been achieved by in vitro immunization with an anti-idiotypic antibody that mimics CEA. 7, 12 CEA is expressed extensively on colon carcinomas, and thus constitutes a good potential target for immunotherapy despite its poor immunogenicity. Vaccines using recombinant CEA (rCEA) produced in vaccinia or baculovirus vectors have been used in several studies. Mice immunized with rCEA developed antibody, DTH, lymphoproliferative and cytotoxic responses, and were protected against challenge with murine colon carcinoma cells expressing human CEA. 13 Patients with colon cancer immunized with rCEA mounted a cytotoxic T lymphocyte (CTL) response against tumor cells loaded with CEA peptides. 14 Patients with colon cancer immunized with rCEA mounted both antibody and T-cell responses against CEA that were enhanced by adding granulocyte/macrophage-colony-stimulating factor (GM-CSF). 15 Unlike several infectious diseases, which are well controlled by humoral responses, solid tumors such as colon carcinoma are likely to require cellular responses for effect. Studies in animals reveal that tumor regression is more often associated with cellular than with humoral immunity. 6 While peptide, protein or glycoprotein vaccines elicit mainly antibody responses, DNA vaccines allow presentation of antigen to the immune system in several ways and have the potential of inducing strong cellular responses. DNA vaccines have been shown to stimulate all three arms of the immune system, that is, antibody, helper T, and cytotoxic T-cell (CTL) responses, 16 to produce immunity in several disease models such as influenza, 17, 18 HIV-1, 19, 20 and hepatitis B, 21 and to protect animals from subsequent challenge. 18 The mechanisms are considered to involve antigen presentation by both myocytes and antigen-presenting cells (APCs), as well as crosspriming between the two MHC paths. Promising effects have been seen in studies using CEA plasmid DNA vaccines. Humoral, proliferative, and DTH responses were observed in pig-tailed macaques immunized with CEA DNA vaccines, 22 and dogs immunized with CEA DNA vaccines mounted humoral and proliferative responses. 23 Protective effects were also seen in tumor challenge experiments after CEA DNA vaccination in mice. 40 Improved immune responses have been observed with antigens fused to T-helper cell epitopes from tetanus toxin, either as a fusion peptide vaccine or as a DNA vaccine. 24, 25, 34 Here we combine the use of plasmid DNA vaccination with truncation of signal peptides of the antigen, as well as the addition of a T-cell epitope, in an attempt to favor the cellular arm of the immune response.
Methods

CEA DNA constructs
A summary of the CEA gene constructs used in this study appears in Figure 1 . The plasmid p91023(B) was a kind gift from Nicole Beauchemin and Clifford Stanners, McGill University, Montreal, Canada. 26 It is a 7385 kb plasmid derived from pBR322. It encodes a full-length clone of human CEA (CEA) (accession number M17303), driven by the adenovirus major late promoter and with an SV40 poly A tail. CEA is 3036 bp long. p91023(B) contains a 5 0 untranslated region (UTR) (bp 1-96), a 5 0 signal sequence (ss) (bp 97-198), the CEA region of interest to us, that is, DCEA (bp 199-2121), a 3 0 ss (bp 2121-2205), and a 3 0 UTR (bp 2206-3036). It contains tetracycline resistance for selection. 3 PCR primers were designed to amplify the CEA gene excluding the signal sequences. To the 5 0 end of the sense strand primer were added an EcoRI site and a consensus eukaryotic ribosomal binding site. 27 The codon for leu 36 was changed from CTC to CTT to generate a unique HindIII site. To the 5 0 end of the antisense primer was added a stop codon and a SalI restriction site for subcloning. The PCR product was cloned into the pGEM T-Easy vector (Promega, Madison, WI). The correct product was verified by DNA sequencing (ABI Prism, Perkin-Elmer, Norwalk, CT) and the DCEA insert was recloned into pKCMV using the SalI and EcoRI sites. The pKCMV vector was previously used in DNA immunization of humans. 20, 28 Figure 1 CEA gene and genetic modifications. The figure shows maps of the CEA protein structure and the genetic modifications used in the study. On the left side of each protein map is the protein designation (bold) and the corresponding plasmid name (italic). CEA is synthesized as a precursor protein with N-and C-terminal signal peptides. Both signal peptides are removed during post-translational processing. The mature protein contains an N-terminal variable region (107 amino acids) and three sets of constant Ig-like repeat regions (178 amino acids each); the C-terminal signal peptide is replaced by a GPI membrane anchor. The p91023(B) plasmid was kindly donated by N Beauchemin. 14 It encodes the wtCEA protein. pKCMVDCEA encodes a CEA protein devoid of both signal sequences. Expression is driven by the CMV promoter and kanamycin resistance is used as a selective marker. A methionine initiator codon was added to the coding sequence of the mature CEA (labelled M in the figure). The C-terminal amino acids 676 and 677 in the two constructs with deleted signal sequences are labelled AS in the figure. In the pKCEA66 plasmid the 15 aa P2 T-cell helper epitope (Q830-L844) of tetanus toxoid was fused to the N-terminus of the DCEA construct. The CEA amino acids 35 and 36 (KL) mark the position of the novel Hind III site where the tet epitope was inserted. The pKCMV plasmid vector was described by Calarota et al.
(kanamycin resistance gene) in compliance with the Swedish regulatory standards for DNA vaccines administered to humans. The correct product was verified and named pKCMVDCEA. Paired oligonucleotides encoding the promiscuous helper T-cell epitope QYIKANSKFI-GITEL (representing amino acids 830-844 of tetanus toxoid) with HindIII sites at both ends were obtained (Life Technologies), annealed and cloned into the HindIII site of pKCMVDCEA, thus creating the new sequence MKLQYIKANSKFIGITEL, replacing the original Nterminal signal sequence of CEA. The correct product was verified by DNA sequencing and named pKCEA66.
Immunofluorescence staining and immunoblot analysis of CEA expression in transfected cells HeLa cells were cultured on coverslips in six-well plates (Nunc, Denmark) in IMDM medium (Life Technologies, Rockville, MD) with 1% l-glutamine, 5% FCS and penicillin/streptomycin (penicillin 50 IU/ml and streptomycin 50 mg/ml, Life Technologies) at 371C until the cells were 60-80% confluent. For transfections, 5 mg of plasmid DNA was mixed with 5 ml 20% glucose and 2.4 ml polyethyleneimine (Sigma-Aldrich, St Louis, MO) in 20 ml water and added to 1 ml of growth medium before adding to the cells. After transfection, the cells were incubated overnight and the medium was changed. At 36-40 hours post-transfection, the cells on coverslips were washed three times in PBS and then blow-dried before they were fixed on the cover glass with À201C acetonemethanol (80:20). The cells were immunostained by a standard double antibody technique 39 using a monkeyanti-CEA IgG diluted 1/2000 as primary antibody and a fluorescein-conjugated, affinity purified goat anti-human IgG (Jackson ImmunoResearch Laboratories Inc., West Grove, PA) as secondary antibody, diluted 1/50 in PBS with 0.01% Tween-20 and 10% NGS. Finally, the cells were counterstained for 5 minutes with a 1/2000 dilution of Hoechst 33258 (500 mg/ml in water).
For testing expression of the plasmid DNAs in immunoblots, D17 canine osteosarcoma or human 293 cells were transfected in 60 mm Petri dishes with 9 mg of p91023(B) (wtCEA), the DCEA clones or the pKCMV vector control plasmid using 30 ml Lipofectin (LifeTechnologies) in DMEM without serum or antibiotics. After 7 hours later, the medium was exchanged for DMEM with 10 % FBS. At 2 days after transfection, the cells were lysed in SDS and analyzed on immunoblots using standard methods, 39 using the monkey-anti-CEA IgG as primary antibody and a horseradish peroxidaseconjugated goat anti-human IgG for detection using a luminol reagent (Amersham-Pharmacia Biotech, UK).
Quantitation of CEA expression in LS174T tumor cells using an enzyme-linked immunosorbent assay (ELISA)
The growth medium from a 3-day culture of LS174T cells was centrifuged at 12,000 rpm for 15 minutes to remove cell debris and the supernatant was stored at À201C until use. The cells were counted, washed three times in PBS, and lysed for 30 minutes on ice in RIPA buffer. 39 Growth medium, cell lysate and rCEA (baculovirus expressed recombinant human CEA protein, Protein Science, Meriden, CT) were then serially diluted with PBS containing 0.5% BSA, 2% normal goat serum (NGS) and 0.05% Tween-20, and preincubated for 1 hour at 371C with monkey-anti-CEA antibodies (SIIDC, Stockholm) diluted at a final concentration of 1/16,000. A 96-well Nunc ImmunoMaxisorb plate was coated with 0.1 mg/well of rCEA antigen diluted in 0.05 M Na 2 CO 3 pH 9.6 overnight at room temperature. The wells were washed four times with 0.9% NaCl, 0.05% Tween-20, blocked 2 hours at 371C with 2% BSA in PBS and then washed four times. The monkey-anti-CEA antibodies, preincubated with appropriate dilutions of growth medium, cell lysate and rCEA, as described above, were added to different wells and incubated for 2 hours at 371C. The wells were washed four times before the addition of goat-anti-human IgG diluted 1/3000 in PBS with 0.5% BSA, 2% NGS and 0.05% Tween-20. The plate was incubated for 2 hours at 371C. After washing the wells four times, the plate was incubated for 15 minutes at 371C with phosphatase substrate (Sigma Diagnostics Inc.) diluted according to the manufacturer's instructions. The reaction was stopped by adding 1 M NaOH and the plate was read at 405 and 650 nm in a double-beam ELISA reader. Unspecific binding of monkey-anti-CEA to the plate and goat-antihuman IgG to the antigen were tested as negative controls. Noninhibited monkey-anti-CEA diluted 1/ 16,000 was used as a positive control.
CEA expression in cell lysates as well as in the supernatant medium was normalized to the number of cells in the original culture. CEA expression on the tumor cells and in the medium was calculated using a standard inhibition curve created by incubating known amounts of rCEA with monkey anti-CEA IgG.
Immunization of C57BL/6 mice with CEA plasmids Three groups of ten 10-12-week-old C57BL/6 (H2 b ) mice were subjected to immunization with plasmid DNA as described below. Plasmid DNAs were transformed into E. coli DH5a (Life Technologies), and purified using Qiagen endotoxin-free Maxi or Mega plasmid preparation kits (Qiagen, Germany) and dissolved at 2 mg/ml in water. One group (931) was immunized intramuscularly (i.m.) in the quadriceps muscle with 100 mg of plasmid pKCEA66, one with 100 mg i.m. of plasmid p91023(B) and 10 with 100 mg i.m. of plasmid pKCMV. After 28 days the mice received a second dose of 100 mg of the respective DNAs, administered in the same way. On day 69 the mice in each group received gene gun immunization (see below) with a total of 5 mg of the respective DNAs administered epidermally at two different locations on the abdomen. Blood samples were taken on days 45 and 88 and before the mice were killed on day 103. Sera were used for tests of humoral immune responses by ELISA (Fig 4) while spleen cells were used for testing T-cell and cytokine responses and for transplantation to SCID mice prior to tumor challenge (5 and 6).
Preparation of DNA-loaded gold beads for gene-gun immunization
Aliquots of 20.7, 20.4 and 21.7 mg gold beads (Microcarrier 1.0 mm, Bio-Rad Laboratories) were placed in three 1.5 ml microcentrifuge tubes. The pKCEA66, p91023(B) and pKCMV plasmids were added at a loading rate of 5.07, 5.15 and 4.84 mg DNA/mg gold, respectively. Each aliquot, containing approximately 2.5 mg DNA, was prepared for injection by standard techniques and was administered using a helium pulsed Accell device (Geniva Inc., Middletown, WI).
ELISA measurement of isotype-specific antibody responses after immunization of C57BL/6 mice
Coating of 96-well Nunc ImmunoMaxisorb plates was performed overnight at room temperature with with 0.1 mg/well of rCEA antigen (rCEA 2 ) diluted in 0.05 M Na 2 CO 3 pH 9.6. The wells were washed four times with 0.9% NaCl, 0.05% Tween-20 and then blocked for 2 hours at 371C with 2% bovine serum albumin (BSA) in PBS. After four washes, serum samples were applied, diluted 1/50 and 1/250 in Buffer A (0.5% BSA and 0.05% Tween-20 in PBS), and incubated for 2 hours at 371C followed by four washes. Goat anti-mouse IgG1, IgG2a, IgG2b, IgG3 or IgA (Caltag) diluted 1/1000 in Buffer A was added and the plates were incubated 90 minutes at 371C. After washing the wells four times the plates were incubated 90 minutes at 371C with alkaline phosphataseconjugated Affinipure rabbit-anti-goat Ig (DAKO) diluted 1/2000 in Buffer A. The wells were washed four times before OPD substrate (o-phenylenediamine dihydrochloride, Sigma, St Louis, MO) diluted in citratephosphate buffer pH 5.0 and H 2 O 2 (one tablet in 10 ml buffer and 3 ml H 2 O 2 ) was added and the plates were incubated 20 minutes at room temperature. The reaction was stopped with 2.5 M H 2 SO 4 and read at 490 and 650 nm in a double-beam ELISA reader. Unspecific binding of the anti-mouse antibodies to the antigen was tested as a control. Monkey-anti-CEA IgG and a known positive serum were used as positive controls. To reveal monkey-anti-CEA binding, a 1/20,000 dilution of an affinity-purified goat-anti-human Ig horseradish peroxidase conjugate (BioRad) was used. LS174T cells subcutaneously at three separate locations 1 day after receiving an intraperitoneal graft of B-, T-, or B+T-cell-depleted spleen cells from C57BL/6 mice previously immunized with DNA constructs expressing either wtCEA (p91023(B)), tetDCEA (pKCEA66) or control plasmid (pKCMV) (see Table 1 ).
Negative selection of immune C57BL/6 spleen cells for SCID transplantation
The C57BL/6 mice were killed on day 103 and blood samples and spleens were collected. Spleens were mashed in 5-10 ml medium with 10% FCS. Cell suspensions were centrifuged briefly to remove large cell aggregates, and the supernatants were centrifuged a second time. Cells were resuspended in 5 ml medium with 10% FCS, counted, and diluted to 2 Â 10 6 cells per ml. T-cell proliferation tests were made on a small portion of the cells. Spleen cells from each group of mice immunized with the same plasmid were pooled and divided into three equal aliquots for negative selection of effector cells using Dynabeads (Dynal AS, Oslo, Norway). In the first aliquot, B cells were removed using B220 antibody-coated beads, in the second aliquot CD4 + and CD8 + cells (T H and T C cells) were removed using L3T4 and Lyt2 antibody-coated beads and in the third aliquot both B cells, CD4 + and CD8 + cells were removed using a combination of all three beads. The antibodies for coating were rat antimouse monoclonal antibodies. The cell separation was 
T-cell stimulation assays
All media used in immunoassays consisted of RPMI 1640 containing 5 or 10% heat-inactivated FCS, 1% penicillin/ streptomycin (final concentration 50 IU/ml and 50 mg/ml, respectively) (Life Technologies), 0.2 mM 2-mercaptoethanol, and 10 mM sodium pyruvate, unless otherwise noted. Spleen cells from the immunized C57BL/6 mice were cultured in RPMI medium with 10% FCS. The following components were added to 96-well plates in 100 ml medium with 10% FCS: medium alone, ConA (final concentration 5 mg/ml), native CEA (10 mg/ml) and rCEA (10 mg/ml), or recombinant control protein (rCP, 10 mg/ml). Subsequently, 2 Â 10 5 cells per well in another 100 ml medium with 10% FCS was added. Each sample was made in triplicate. Cells were cultured at 371C for 5 days.
3 H-labelled thymidine (50 ml per well, 1 mCi) was added and the cells were incubated for another 16 hours before they were harvested in a Harvester 96 (Tomtec, CT) and the incorporation of thymidine by the cells was measured in a liquid b-scintillation counter (Wallac Micro Beta Triluxe TM , Turku, Finland). The SI was calculated by dividing the mean cpm values from the triplicate CEA stimulated wells with the mean cpm of the medium control wells.
Production of IFN-g and IL-4 by stimulated spleen cells
After 48 hours stimulation of spleen cells from immunized C57BL/6 mice with rCEA, as described above, supernatant was removed for cytokine ELISA. This was performed by using a Quantikine s murine kit (R&D Systems, Europe Ltd) for mouse IFN-g and mouse IL-4 according to the manufacturer's instructions. Supernatants, standard reagents and a control were placed in wells coated with monoclonal antibodies specific for mouse IFN-g or IL-4. The plates were incubated for 2 hours at 371C and then washed five times with washing buffer. Horseradish peroxidase conjugate against mouse IFN-g and IL-4 were added and the plates were incubated another 2 hours. The wells were washed five times before the addition of substrate solution, containing hydrogen peroxide and tetramethylbenzidine (TMB), and the plates were incubated 30 minutes at room temperature. The reaction was stopped by adding stop solution containing hydrochloric acid, and the plates were read at 450 and 650 nm in a double-beam ELISA reader.
Results
Wild-type and mutated CEA show different intracellular expression patterns
The DNAs tested for expression in D17 or 293 cells were wtCEA represented by p91023(B), 3 three clones of DCEA with deleted signal sequences (pKCMVDCEA clones 6 and 8) and pKCEA66, where the promiscuous helper Tcell epitope QYIKANSKFIGITEL (representing amino acids 830-844 of tetanus toxoid) was inserted at the Nterminus of the CEA in pKCMVDCEA (Fig 1) and one clone of a negative vector control (pKCMV). In Figure 2 , the wtCEA protein, expressed from the p91023(B) plasmid, shows a characteristic expression pattern of a plasma membrane protein, with white arrows in panel a indicating its presence in the ruffled edge and cytoplasmic projections of the cell. The presence of CEA in small patches is also visible in the left field in panel a, which may represent raft localization typical of GPI-anchored proteins. In contrast, the majority of the DCEA protein was found in aggregates in a perinuclear (see arrow) or cytoplasmic distribution, while only a minority of the DCEA protein was observed on the membrane (Fig 2,  panel b) . CEA protein expressed from the pKCEA66 vector gave rise to a homogeneous cytoplasmic fluorescence with marked vacuolization (white arrows in panel c). The pKCMV vector was negative (data not shown).
Cell lysates from transfected cells were analyzed on immunoblots (Fig 3) . rCEA protein was used as a positive control and migrated at 130-200 kDa; DCEA (clones 6 and 8) migrated at 130 kDa, while wtCEA (p91023(B)) had bands both at 130 and 200 kDa. rCEA purified from a baculovirus expression system is differently glycosylated and has a size of 120 kDa with considerable size variation on immunoblots. Eliminating the signal sequences also eliminates glycosylation (since the protein is not translocated to the ER). p91023(B) encodes full-length CEA, which is glycosylated, although overexpression and aberrant intracellular transport in the transfected cells may limit glycosylation of some full-length CEA molecules, explaining the appearance of two bands.
Humoral immune responses in C57BL/6 mice immunized with the pKCEA66 plasmid favor IgG1 over IgG2a
Humoral immune responses after plasmid DNA immunizations were tested by ELISA for CEA reactive antibodies of isotypes IgG1, IgG2a, IgG2b, IgG3, IgM and IgA. In Figure 4 we show the results for IgG1 (Panel a) and IgG2a (panel b). IgG2b-specific responses were similar to IgG2a. The IgG3, IgM and IgA responses were low and did not differ significantly between the groups of immunized mice. The response profiles shown were carried out with sera collected at the time of killing, on day 103. The antibodies were directed against both native and rCEA.
All mice immunized with plasmid pKCEA66 had a strong IgG1 response (Fig 4a) . The IgG1 response was stronger than any of the other subclasses. Three of 10 mice immunized with plasmid p91023(B) also developed strong IgG1 responses, while none of the mice immunized with the empty plasmid pKCMV had a significant humoral response. The immunization schedule was as described in Methods. These results show that CEAspecific humoral immune responses were raised against the wtCEA plasmid p91023(B) as well as against the pKCEA66 plasmid, but that these responses were quantitatively different, with a response in all mice receiving pKCEA66. IgG2a responses were generally of lower amplitude occurring in five mice responding to pKCEA66 compared to two in the group receiving p91023(B). C57BL/6 mice immunized with plasmids encoding wtCEA or tetDCEA mount T-cell-specific responses to CEA Proliferation of lymphocytes in response to CEA antigen following plasmid immunization was analyzed in parallel with the humoral response. A small portion of pooled spleen cells collected from each group of immunized C57BL/6 mice was used for T-cell proliferation assays. As shown in Figure 5 , mice immunized with plasmid pKCEA66 developed a cell-mediated response with a mean SI of 6.2. Spleen cells from mice immunized with plasmid p91023(B) had a mean SI of 4.0 and spleen cells from mice immunized with plasmid pKCMV showed no significant reactivity to CEA (SI of 1.2). A SI above 2 was considered positive. Spleen cells from the group immunized with pKCEA66 showed higher activity. Provided that the cellular immune responses reflect the humoral response pattern, this may be explained by a larger number of mice reacting to pKCEA66. In preliminary experiments, we observed that C57BL/6 mice mounted a cellular immune response also to another pKCMVDCEA plasmid, which encodes a CEA gene devoid of signal sequences but lacking the p2 epitope from tetanus toxoid (data not shown).
CEA-stimulated spleen cells from immunized C57BL/6 mice produce IFN-g but not IL-4
Culture supernatants were sampled for cytokine measurements after 48 hours stimulation of spleen cells with CEA antigen. Mean values of the cytokine measurements (triplicate tests) for IFN-g and IL-4 are shown in Figure 6 . Spleen cells from both groups (pKCEA66 and p91023(B)) showed high IFN-g production while spleen cells from animals immunized with the pKCMV vector control produced almost no IFN-g (Fig 6, panel a) . The IL-4 production was low in all three groups (Fig 6, panel  b) , with some nonspecific production detected in mice immunized with the empty control plasmid pKCMV. These results show that the CEA plasmids induced a T H 1 response in the mice, since IFN-g is mainly produced by T H 1 cells while IL-4 is produced by T H 2 cells. As mentioned above, the group given pKCEA66 is likely to contain a larger number of reacting individuals, so the differences between responding individuals in the groups receiving the CEA-expressing plasmids may not be significant.
Spleen cells from pKCEA66-immunized C57BL/6 mice reduce both tumor frequency and tumor growth rate in SCID mice after challenge with CEA tumor cells Spleen cells from the plasmid-immunized C57BL/6 mice were transplanted to SCID mice intraperitoneally, after a negative selection had been performed where B, T or both B and T cells were removed. The SCID mice were then inoculated with human tumor cells in three doses and the tumor growth was measured (Fig 7 and Table 1 The tumor take frequency as well as tumor growth differed significantly (Po.01) between animals receiving spleen cells from pKCEA66-immunized C57BL/6 mice, and animals in all other groups. In the group receiving pKCEA66-immunized spleen cells, only four of 10 animals developed tumors at all, and only in the highest tumor cell dose (10 6 tumor cells) ( Table 1 ). The growth rate and final size of these tumors in the individuals receiving spleen cells from pKCEA66-immunized mice was also strongly diminished (Fig 7) . In groups of SCID mice receiving spleen cells from C57BL/6 mice immunized with p91023(B) or the pKCMV vector control, all the tumor take rates were similar and did not differ significantly from the tumors of SCID mice receiving no spleen cells.
Transplantation of effector-depleted splenocytes from the plasmid-immunized C57BL/6 mice was carried out according to the schedule described in Methods. The effector cell depletions had no significant effect on tumor take frequency or growth within the different groups of SCID mice. In all groups except one, tumor take frequency was little affected and tumor growth was rapid (not shown). The strong suppression of tumors after transplantation of spleen cells derived from pKCEA66-immunized mice, however, remained unaltered in the three subgroups receiving effector-depleted splenocytes, while the rapid tumor growth was seen in all other animals. The remaining effector cells after these depletions were assumed to consist of T and NK cells (B-cells depleted), B and NK cells (T-cells depleted) and NK cells (B-and T-cells depleted). It is therefore logical to assume that the remaining cells after depletion of B and T cells (i.e. NK cells, CD1d restricted NKT cells, monocytes and possibly residual antibodies) mediate the reductive effects on tumor cell growth. Since the efficiency of cell depletion was 92-97%, it cannot be ruled out, however, that B or T cells remaining after the depletions may have contributed to this effect. Experiments with NK-cell depletion were not successful using available reagents.
Discussion
CEA is expressed extensively on human colon carcinomas and is well characterized. Despite its poor immunogenicity, CEA continues to be a promising target for antigenspecific immunotherapy in humans. The goal of cancer vaccines is mainly the generation of antigen-specific cellular immune responses. [29] [30] [31] Early efforts to induce antitumor immune responses against colon cancer involved the use of recombinant protein vaccines. While some success was achieved, there is reason to believe that DNA vaccination may be effective in inducing cellmediated immune responses.
We used a plasmid DNA vaccine encoding human CEA devoid of its signal sequences (DCEA) and compared it to a plasmid DNA encoding full-length CEA (Fig 1) . We hypothesized that protein encoded by DCEA would better localize antigen to the cytosol, increase proteasomal degradation and MHC class I presentation 32 than would rCEA protein or glycoproteins expressed from DNA encoding full-length CEA containing signal peptides. Presentation of GPI-anchored membrane proteins occurs mainly following endocytosis and sorting to the late endosomal MHC class II loading compartment, perhaps aided by recognition of the GPI anchor by CD1d of APCs. 36 As expected, the cellular expression patterns of wtCEA and DCEA were markedly different. The wtCEA protein was localized diffusely on the membrane but also concentrated in small patches as expected for a raftassociated GPI-anchored protein. In contrast, the DCEA protein accumulated in aggregates with a perinuclear or cytoplasmic distribution. This pattern suggests that the Figure 4 Isotype-specific humoral responses to immunization with CEA plasmid DNAs. Sera were collected on day 103 after three immunizations with CEA plasmid DNA. A total of 10 mice in each of the three groups of C57BL/6 mice received pKCEA66 (expressing the tetDCEA protein), p91023(B) (expressing the wtCEA protein) or pKCMV vector DNA as described in Methods. Mouse Ig isotype ELISA was performed for IgG1, IgG2a, IgG2b, IgG3, IgM and IgA. (a) Individual IgG1 responses and (b) IgG2a responses. The IgG2b responses were similar to the IgG2a while the remaining tests showed insignificant differences between the three groups of immunized mice. In the positive control, monkey anti-CEA IgG was added before the isotype-specific goat anti-mouse Ig, while in the negative control, the monkey anti-CEA IgG was omitted.
DCEA protein is defective in intracellular transport, consistent with the absence of signal peptides.
Epitopes from the tetanus toxoid have been used widely for the development of vaccines against infectious agents and cancer. In humans, a pre-existing immune response is commonly due to tetanus vaccination. Examples of such vaccine designs include the use of separate peptides from tumor and tetanus toxoid, 37 recombinant fusion proteins between tetanus toxoid and pathogen proteins 38 or DNA vaccines consisting of fusion proteins between tetanus toxoid and tumor antigens such as CEA peptide sequences. 34 Based on the observation that a tetanus toxoid epitope is a promiscuous helper epitope and augments cellular immune responses to CEA, 34 we decided to include the p2 tetanus helper epitope (Q830-L844) in our vaccine construct. The resulting tetDCEA construct directed the synthesis of a protein with a diffuse cytoplasmic distribution accompanied by a marked vacuolization, in contrast to the aggregated perinuclear localization of the DCEA construct or the cell membrane localization of native CEA. It is conceivable that this phenotypic effect may be connected to the function of the translocation domain (H N ) of tetanus toxin, from which the epitope is derived.
In immune sera from C57BL/6 mice, we observed a predominance of IgG1 over IgG2a CEA-specific antibodies after primary immunization and boosting with DNA (either wtCEA (p91023(B)) or pKCEA66), whereas boosting with 100 mg CEA glycoprotein resulted in an approximately equal distribution between IgG1 and IgG2a (data not shown). Both plasmids gave rise to significant CEA-specific activation of cellular immune responses, indicating that removal of the signal sequences in the pKCEA66 plasmid did not decrease its ability to stimulate the cellular immune system compared to the wtCEA (p91023(B) plasmid). Since the responses elicited by the CEA DNA vaccination were of Th1 as well as Th2 type, we conclude that several arms of the immune system were activated.
The immunological effects of cellular localization of antigen on immune responses are incompletely studied. When given as DNA vaccines to mice, cytoplasmic ovalbumin (OVA) generated a higher IgG2a but lower IgG1 and cytotoxic T-cell responses than did secreted OVA. 29 A chimeric antigen (ZZN4) with or without the signal sequence for human tissue plasminogen activator gave comparable antibody responses when given to mice as DNA vaccines. 33 Unexpectedly, spleen cells from C57BL/6 mice immunized with the pKCEA66 plasmid alone could totally inhibit the growth of a CEA-containing tumor in SCID mice, while immunization with the wtCEA plasmid did not differ from the pKCMV control plasmid.
An important object of CEA-based tumor therapy is to break tolerance against this self-antigen. Since the mouse is not tolerant to human CEA, our present mouse model cannot claim to represent a relevant model for MHC class I restricted cytotoxicity against human CEA. The present results regarding protection from tumor growth are thus subject for discussion. They may be caused by specific Tcell responses, antibody-dependent cellular cytotoxicity (ADCC), activated NK or NKT cells, monocytes or a combination. Our experiments with transplantation of effector-depleted spleen cells prior to tumor challenge of SCID mice demonstrate that neither depletion of B cells, T cells nor a combination of the two significantly influenced the tumor take frequency or the tumor growth rate within any of the SCID mouse groups. Instead, the decisive determinant for tumor rejection was the plasmid used for producing the immunocompetent spleen cells. This indicates that the non-B/T-cell fraction might be essential. A direct assessment of the importance of such cell populations in DNA-directed immune responses will be included in phase I trials of these plasmid vaccines in human subjects. In our preliminary experiments of a similar design, complete tumor protection was also obtained after transfer of spleen cells from C57BL/6 mice immunized with the wtCEA plasmid (p91023(B)) followed by boosting with CEA protein (data not shown). This indicates, as does the observation that strong IgG1 responses are induced after immunization with the CEA plasmids, that an antibody-mediated mechanism may be beneficial for a vigorous antitumor response.
It might be argued that the difference in tumor rejection efficiency between the SCID mice treated with pKCEA66-immunized spleen cells and those treated with p91023(B)-immunized cells could be explained by the greater number of reactive C57BL/6 mice. However, the antitumor effect in the group of SCID mice receiving spleen cells from pKCEA-immunized C57BL/6 is qualitatively different, since tumor growth in this group remained negligible for a period up to 27 days. This effect must depend on the structural changes introduced in the pKCEA66 gene product, but the relative contribution of each of these changes remains to be elucidated.
These data confirm that DNA vaccination offers new ways of stimulating the immune system and suggest that further attention should be directed at manipulation of protein-targeting signals, so as to alter processing and presentation to the immune system. Of particular interest is the prospect of enhancing protective responses and thus ultimately tumor destruction in humans. Our data indicate that DNA vaccination and manipulation of antigen are two strategies that deserve further exploration in the challenging task of recruiting the full power of the immune system in immunotherapy against colon and other carcinomas.
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